1. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
With an analyst consensus upside of 126.9%, Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) ranks among the under-the-radar stocks with massive upside for 2026.
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) drew fresh analyst attention after multiple updates tied to the rollout of PALSONIFY and the company’s broader endocrine pipeline.
On May 11, 2026, Oppenheimer lowered its price target on Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) to $84 from $87 while maintaining an “Outperform” rating following quarterly results.
The firm pointed to continued enrollment in the Phase 3 carcinoid syndrome study and ongoing pivotal and Phase 2 trials for atumelnant in adult and pediatric congenital adrenal hyperplasia (CAH), with a Phase 2/3 study in ACTH-dependent Cushing’s syndrome expected to begin soon. Oppenheimer also said it is watching for initial clinical data from CRN09682 in neuroendocrine tumors later this year.
That followed Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)’s May 7, 2026, first-quarter report, which showed revenue rising to $10.7 million from $0.4 million a year earlier, including $10.3 million in net product revenue from PALSONIFY. The company received 232 enrollment forms during the quarter, while 263 unique healthcare providers prescribed the treatment within its first two quarters on the market. About 70% of patients on PALSONIFY at quarter-end were receiving reimbursed therapy.
Meanwhile, Citizens lowered its price target on Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) to $95 from $97 on May 8, 2026, while keeping an “Outperform” rating, citing PALSONIFY’s expanding prescriber adoption and improving reimbursement trends.
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) ended the quarter with $1.3 billion in cash, cash equivalents, and investment securities and maintained its 2026 GAAP operating expense guidance of $600 million to $650 million.
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is engaged in developing and marketing innovative treatments for rare endocrine diseases and endocrine-related tumors. The company offers a range of therapies that are currently in different stages of clinical trials. These include Paltusotine, Atumelnant, CRN09682, oral GLP-1, and GIP nonpeptide.
While we acknowledge the potential of CRNX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CRNX and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 9 Best Cloud Stocks to Buy as Azure Growth Hits 40% and 10 Best Nuclear Energy Stocks to Buy as SMRs Go Mainstream.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.
